Claims for Patent: 12,303,497

Summary for Patent: 12,303,497

Title:	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
Abstract:	Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.
Inventor(s):	Margaret K. Yu
Assignee:	Aragon Pharmaceuticals Inc
Application Number:	US18/498,542
Patent Claims:	1. A method for increasing overall survival and progression-free survival in a patient having metastatic castration-sensitive prostate cancer, said method comprising administering apalutamide in a therapeutically effective amount in combination with androgen deprivation therapy to the patient, wherein administration of the apalutamide in combination with androgen deprivation therapy provides an increase in the overall survival rate relative to the overall survival rate of a population of patients with the metastatic castration-sensitive prostate cancer, said population having been administered a placebo in combination with an androgen deprivation therapy, and wherein administration of the apalutamide in combination with androgen deprivation therapy provides an increase in the progression-free survival rate of the patient relative to progression-free survival rate of a population of patients with the metastatic castration-sensitive prostate cancer, said population having been administered a placebo in combination with an androgen deprivation therapy. 2. The method of claim 1, wherein the apalutamide is administered orally to the patient. 3. The method of claim 1, wherein the apalutamide is administered orally to the patient at a dose of about 240 mg per day. 4. The method of claim 1, wherein if the patient experiences a greater than or equal to Grade 3 toxicity or an intolerable side effect, holding dosing of apalutamide until symptoms of the greater than or equal to Grade 3 toxicity improve to less than or equal to Grade 1 or original grade; and resuming daily oral administration of apalutamide in an amount of about 240 mg, 180 mg, or 120 mg. 5. The method of claim 4, wherein daily oral administration of apalutamide is resumed in an amount of about 180 mg. 6. The method of claim 4, wherein daily oral administration of apalutamide is resumed in an amount of about 120 mg. 7. The method of claim 1, wherein the apalutamide is used in combination with bilateral orchiectomy. 8. The method of claim 1 wherein the apalutamide is administered in combination with at least one gonadotropin-releasing hormone (GnRH) agonist or antagonist. 9. The method of claim 8, wherein the at least one GnRH agonist or antagonist is or comprises leuprolide, buserelin, naferelin, histrelin, goserelin, deslorelin, degarelix, ozarelix, ABT-620 (elagolix), TAK-385 (relugolix), EP-100, KLH-2109 or triptorelin. 10. The method of claim 1, wherein the apalutamide is not co-administered with: (a) a medication that is a strong CYP2C8 or CYP3A4 inhibitor; (b) a medication that is primarily metabolized by CYP3A4, CYP2C19, or CYP2C9; (c) a medication that is a substrate of UDP-glucuronosyl transferase; or (d) a medication that is a substrate of P-glycoprotein, breast cancer resistance protein or organic anion transporting polypeptide IBI. 11. The method of claim 1, wherein the treatment comprises (a) administering a daily oral dose of apalutamide in an amount of about 240 mg; (b) if the patient experiences a greater than or equal to Grade 3 toxicity or an intolerable side effect, holding dosing of apalutamide until symptoms of the greater than or equal to Grade 3 toxicity improve to less than or equal to Grade 1 or original grade; and resuming daily oral administration of apalutamide in an amount of about 240 mg, 180 mg, or 120 mg. 12. The method of claim 1, wherein administration of apalutamide in combination with androgen deprivation therapy provides (i) an increase in overall survival and a 33% reduction in risk of death or (ii) an increase in progression free survival and a 52% reduction in risk of radiographic progression or death.